The Food and Drug Administration has not evaluated these statements. This product is not designed to diagnose, treat, cure, or prevent any medical condition. Not intended for human consumption.Retatrutide is a synthetic multi-agonist peptide designed to interact with glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptor pathways. It is investigated in metabolic and endocrine research for its effects on energy-regulation signaling, glucose-metabolism dynamics, and lipid-utilization pathways. In vitro and preclinical studies commonly examine its influence on receptor-mediated signaling cascades, metabolic-rate modulation, and mechanisms associated with nutrient-partitioning and energy-balance regulation.